Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in Generalized Myasthenia Gravis (LUMINESCE)
NCT04963270Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Satralizumab with Placebo (2 arms). Primary endpoint: Myasthenia Gravis Activities of Daily Living at 24 weeks. Started Oct 2021; status: terminated.
02
Drugs
satralizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04963270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963270.